NCT03766490

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

A Prospective, Single-arm, Multicenter Study of Anlotinib Hydrochloride Combined With First-generation EGFR TKIs as Second-line Treatment in Acquired (Non-T790M Mutation) Resistance Advanced Non-small Cell Lung Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high. Studies have shown that bevacizumab combined with EGFR TKI have a good trend of benefit. This study is aimed to evaluate the efficacy and safety of Anlotinib Hydrochloride combined with first-generation EGFR TKIs as second-line treatment in advanced non-small cell lung cancer . The patients with IV non-small lung cancer have acquired resistance to prior first-generation EGFR TKIs and have non-T790M mutation.

Conditions

• Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	Anlotinib Hydrochloride	Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
DRUG	Gefitinib	Tablet, P.O. 250mg qd
DRUG	Icotinib	Tablet, P.O. 125mg tid

Timeline

• Start date: 2019-03-30
• Primary completion: 2019-12-20
• Completion: 2020-12-20
• First posted: 2018-12-06
• Last updated: 2019-01-30

Locations

1 site across 1 country: China